Venous admixture in COPD: pathophysiology and therapeutic approaches

Christopher B Cooper, Bartolome Celli, Christopher B Cooper, Bartolome Celli

Abstract

Chronic obstructive and interstitial lung diseases impair pulmonary gas exchange leading to wasted ventilation (alveolar dead space) and wasted perfusion (venous admixture). These two fundamental types of abnormality represent opposite ends of the spectrum of ventilation-perfusion mismatch with V/Q ratios of infinity and zero. Treatment approaches that improve airway function, reduce air trapping and hyperinflation have received much attention and might be successful at ameliorating the problems associated with high V/Q. However, in patients with low V/Q abnormality in whom venous admixture leads to hypoxemia, there are few therapeutic options. Indeed, some patients are refractory to treatment with supplemental oxygen particularly during exercise. Theoretically these patients could benefit from an intervention that increased mixed venous oxygen content thereby ameliorating the deleterious effects of venous admixture. In this perspective article we discuss the mechanisms whereby venous admixture contributes to hypoxemia and reduced oxygen delivery to tissues. We explore methods which could potentially increase mixed venous oxygen content thus ameliorating the deleterious effects of venous admixture. One such intervention that warrants further investigation is the therapeutic creation of an arterio-venous fistula. Such an approach would be novel, simple and minimally invasive. There is reason to believe that complications would be minor leading to a favorable risk-benefit analysis. This approach to treatment could have significant impact for patients with COPD but should also benefit any patient with chronic hypoxemia that impairs exercise performance.

Figures

Figure 1
Figure 1
Theoretical calculations based on the classical shunt equation: (a) Effect of venous admixture or pulmonary shunt fraction (Q˙S/Q˙T) on arterial oxygen content (CaO2) for a given mixed venous oxygen content (Cv¯O2) assuming ideal pulmonary capillary oxygen content is 0.20 L/L; (b) effect of Cv¯O2 on CaO2 for a given Q˙S/Q˙T also assuming ideal pulmonary capillary oxygen content is 0.20 L/L; and (c) effect of an arteriovenous stula expressed as a fraction of cardiac output (Q˙F/Q˙T) on Cv¯O2 for a given CaO2 assuming systemic capillary oxygen content is 0.15 L/L.
Figure 2
Figure 2
Effect of supplemental oxygen on ventilation-perfusion mismatch (low V˙/Q˙) and intra-pulmonary shunt (V˙/Q˙=0). When breathing 100% oxygen from a closed circuit (FIO2 100%), even lung regions with very low alveolar ventilation (on the left) should see an increase in alveolar oxygen tension (PAO2) to greater then 100 mm Hg in which case the blood draining that region will be fully saturated. By contrast, regions of intra-pulmonary shunt (on the right) experience no ventilation and the blood draining those regions has an oxygen content equal to the mixed venous blood (Cv¯O2).

References

    1. Cooper CB. Determining the role of exercise in patients with chronic pulmonary disease. Med Sci Sports Exerc. 1995;27:147–157.
    1. Astrand P-O, Rodahl K. Textbook of work physiology. McGraw-Hill; 1970.
    1. West JB. Ventilation/blood o w and gas exchange. 4th ed. Oxford: Blackwell Scienti c Publications; 1985.
    1. Wagner PD. Ventilation/perfusion relationships. Clin Physiol. 1981;1:437–451.
    1. Cooper CB, Storer TW. Exercise Testing and Interpretation: A Practical Approach. New York: Cambridge University Press; 2001.
    1. Wagner PD. New ideas on limitations to VO2max. Exerc Sport Sci Rev. 2000;28:10–14.
    1. Spiro SG, Hahn HL, Edwards RH, et al. An analysis of the physiological strain of submaximal exercise in patients with chronic obstructive bronchitis. Thorax. 1975;30:415–425.
    1. Marchetti N, Panetta N, Criner G. The effect of lung hyperin ation in COPD on cardiac function. Proc Am Thorac Soc. 2008;177:A782.
    1. Montes de Oca M, Rassulo J, Celli BR. Respiratory muscle and cardiopulmonary function during exercise in very severe COPD. Am J Respir Crit Care Med. 1996;154:1284–1289.
    1. Wagner PD. Diffusive resistance to O2 transport in muscle. Acta Physiol Scand. 2000;168:609–614.
    1. Severinghaus JW. Simple, accurate equations for human blood O2 dissociation computations. J Appl Physiol. 1979;46:599–602.
    1. John M, Lange A, Hoernig S, et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol. 2006;111:365–370.
    1. Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29:923–929.
    1. Moore GE, Parsons DB, Stray-Gundersen J, et al. Uremic myopathy limits aerobic capacity in hemodialysis patients. Am J Kidney Dis. 1993;22:277–287.
    1. Cooper CB. Exercise in chronic pulmonary disease: aerobic exercise prescription. Med Sci Sports Exerc. 2001;33:S671–679.
    1. Fabbri L, Pauwels RA, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary updated 2003. COPD. 2004;1:105–141. discussion 103—104.
    1. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance United States, 1971—2000. MMWR Surveill Summ. 2002;51:1–16.
    1. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperin ation and its impact on exercise and function. Am J Med. 2006;119:21–31.
    1. Casaburi R, Petty TL. Principles and practice of pulmonary rehabilitation. Philadelphia: WB Saunders Company; 1993.
    1. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperin ation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743–1748.
    1. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperin ation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840.
    1. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:86–94.
    1. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–1413.
    1. Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis. 1991;143:9–18.
    1. Casaburi R, Porszasz J, Burns MR, et al. Physiologic benets of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155:1541–1551.
    1. Cooper CB. Long-term oxygen therapy. In: Casaburi R, Petty TL, editors. Principles and practice of pulmonary rehabilitation. Philadelphia: WB Saunders Company; 1993.
    1. Emtner M, Porszasz J, Burns M, et al. Bene ts of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med. 2003;168:1034–1042.
    1. Markovitz GH, Cooper CB. Exercise and interstitial lung disease. Curr Opin Pulm Med. 1998;4:272–280.
    1. Ekblom BT. Blood boosting and sport. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:89–98.
    1. Levine BD, Stray-Gundersen J. Living high-training low”: effect of moderate-altitude acclimatization with low-altitude training on performance. J Appl Physiol. 1997;83:102–112.
    1. Gaudard A, Varlet-Marie E, Bressolle F, et al. Drugs for increasing oxygen and their potential use in doping: a review. Sports Med. 2003;33:187–212.
    1. Brittinger WD, Twittenhoff WD, Schwarzbeck A, et al. Haemodynamic effects of A-V shunts and their clinical signi cance. Proc Eur Dial Transplant Assoc. 1972;9:642–649.
    1. Cooper C, Galindo J, Posadas R, et al. Improved exercise performance with supplemental oxygen predicts a bene cial response to therapeutic arterio-venous stula in patients with severe COPD. Chest. 2007;132:453S.

Source: PubMed

3
Subskrybuj